Page 1

RACE ONCOLOGY ■ ■ + ASX Announcement September 2021 Quarterly Activity Report and Appendix 4C First patient dosed in the Phase 1b / 2 AML trial at Chaim Sheba , Israel Zantrene found to kill melanoma cells that overproduce FTO in preclinical interim results Significant progress made in our preclinical and clinical programs despite COVID - 19 restrictions in NSW . Race updates on preclinical and clinical progress 28 September 2021 - The September 2021 quarter ( Q1 FY 2022 ) was highlighted by the first patient being dosed in the Phase 1b / 2 combination Acute Myeloid Leukemia ( AML ) study , where Zantrene is being trialled in patients with relapsed / refractory ( R / R ) AML ( ASX announcement : 9 August 2021 ) . A second highlight was the interim preclinical results from our University of Newcastle collaborators that showed Zantrene to be highly effective at killing a diverse range of melanoma cell subtypes at low ( sub - chemotherapeutic ) concentrations . The data also showed a close association between FTO protein levels in the cancer cells and sensitivity to Zantrene ( ASX announcement : 30 September 2021 ) . Late in the quarter , Race provided an update on the broader preclinical and clinical programs given some Covid - related slowdowns ( ASX announcement : 30 September 2021 ) . In sum , we continue to make significant progress on all programs and will be further updating this quarter . Key events of the quarter On 9 August 2021 , Race announced that the first patient was dosed in its Phase 1b / 2 AML clinical trial at the Chaim Sheba Medical Center Israel under Principal Investigator Prof. Arnon Nagler , MD . Treating the first patient is an important step in any trial . We look forward to the full clinical data set and trust this may build upon earlier observations reporting an encouraging 40 % overall clinical response rate ( ASX announcement : 16 June 2020 ) . On 30 September 2021 , Race announced that Zantrene kills melanoma cancer cells that overproduce FTO . The preclinical program led by University of Newcastle researchers Professor Zhang and Associate Professor Jin identified that Zantrene sensitivity is correlated with FTO levels , and that high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells . The results support future Race Oncology Ltd ABN 61 149 318 749 Registered office : L36 , 1 Macquarie Place , Sydney NSW 2000 www.raceoncology.com